Treace Announces Grant of U.S. Patent and Allowance of U.S. Patent Application on Bone Positioner Technology for Bunion Correction
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced the granting of U.S. Patent No. 11,185,359 for a "Bone Positioning Guide" related to bunion correction surgery. Additionally, the U.S. Patent Office issued a Notice of Allowance for a pending application on similar techniques. These developments enhance Treace's patent portfolio, which now includes over 35 granted patents and 60 pending applications globally. CEO John T. Treace emphasized the importance of these patents in reinforcing the company's commitment to innovation in bunion surgery.
Positive
- Strengthened intellectual property position with the granting of U.S. Patent No. 11,185,359.
- Notice of Allowance for a pending patent application related to bunion correction techniques.
- Expansion of Treace's patent portfolio to over 35 granted patents and 60 pending applications.
Negative
- None.
Details
News Market Reaction – TMCI
The recorded move for TMCI in the trading session of this news was +3.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PONTE VEDRA, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announced today that the United States Patent and Trademark Office granted to the Company U.S. Patent No. 11,185,359, titled “Bone Positioning Guide,” and also issued a Notice of Allowance for the Company’s pending U.S. Patent Application No. 17/353,431, titled “Bone Positioning and Preparing Guide Systems and Methods.”
The granted patent relates generally to techniques, including for use in bunion correction surgery, for moving the first metatarsal with a positioning instrument. The allowed patent application relates generally to techniques for correcting a bunion deformity involving the use of a bone preparation guide and a positioning instrument. The newly granted patent and allowed patent application expand Treace’s comprehensive patent coverage on instrumented bunion correction techniques with particular emphasis on metatarsal bone positioning instrumentation, a product category Treace pioneered through its innovative development efforts.
“We are pleased that the Patent Office continues to recognize the novel advances made by Treace Medical. The addition of this recent patent grant and the notice of allowance further strengthen our intellectual property position and highlight our commitment to innovation in advancing the surgical treatment of bunion patients,” said John T. Treace, CEO of Treace Medical.
Treace actively protects its innovations through patenting and is gratified that the United States Patent and Trademark Office and patent agencies worldwide continue to recognize the novelty of Treace’s contributions to the field. The Company has a global portfolio of over 35 granted patents and 60 pending patent applications, including over 30 pending US patent applications. Additional details on Treace’s patent coverage can be found at www.treace.com/patents.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system - a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot which could provide further support to hallux valgus patients. For more information, please visit www.treace.com.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.